Arabella Buchmann

Dr. Arabella Buchmann

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2019 in Multiple Sclerosis Journal
Verified
Journal Article
Closed access
PDF file
GBGabriel Bsteh
Gabriel Bsteh
KBKlaus Berek
Klaus Berek
HHHarald Hegen
Harald Hegen
BTBarbara Teuchner
Barbara Teuchner
ABArabella Buchmann
Arabella Buchmann
TBThomas Berger
Thomas Berger
Background: Serum neurofilament light chain (sNfL) levels and peripapillary retinal nerve fiber layer (pRNFL) are both emerging biomarkers of neuro-axonal damage in multiple sclerosis (MS). However, data on the relation between sNfL and pRNFL are scarce. Objective: We aimed to determine the relation of sNfL levels with pRNFL thinning in a large cohort of relapsing–remitting (RR) MS patients. Methods: We identified 80 patients from a prospective, 3-year observational study on retinal changes in RRMS with annual blood samples available. sNfL levels were measured using single-molecule array (SimoaTM) assay. Annualized loss of pRNFL (aLpRNFL) was determined by individual linear regression models. Correlations between single and repeated sNfL levels and aLpRNFL were analyzed using multivariate linear regression and mixed-effect models. Results: After correction for sex, age, and baseline sNfL, an sNfL increase of 10 pg/mL was associated with an aLpRNFL of −0.7 µm (95% confidence interval (CI): (−1.3, −0.2), p < 0.001). Patients with ⩾2 sNfL measurements >75th percentile displayed higher aLpRNFL (2.2 µm, standard deviation (SD) 0.6) compared to patients with no sNfL measure >75th percentile (0.4 µm, SD 0.2, p < 0.001). Between 15% and 20% of the aLpRNFL variance could be predicted from sNfL levels. Conclusion: sNfL levels contribute to the prediction of retinal thinning in patients with RRMS, strengthening its value as a biomarker of neuro-axonal damage.

1 March 2023 in European Journal of Neurology
Verified
Journal Article
Open access
ABArabella Buchmann
Arabella Buchmann
LPLukas Pirpamer
Lukas Pirpamer
DPDaniela Pinter
Daniela Pinter
MVMargarete Voortman
Margarete Voortman
BHBirgit Helmlinger
Birgit Helmlinger
MKMichael Khalil
Michael Khalil
Background and purpose: Serum neurofilament light chain (sNfL) is a promising biomarker of neuroaxonal damage in persons with multiple sclerosis (pwMS). In cross‐sectional studies, sNfL has been associated with disease activity and brain magnetic resonance imaging (MRI) changes; however, it is still unclear to what extent in particular high sNfL levels impact on subsequent disease evolution.Methods: sNfL was quantified by an ultrasensitive single molecule array (Simoa) in 199 pwMS (median age = 34.2 years, 64.3% female) and 49 controls. All pwMS underwent 3‐T MRI to assess global and compartmental normalized brain volumes, T2‐lesion load, and cortical mean thickness. Follow‐up data and serum samples were available in 144 pwMS (median follow‐up time = 3.8 years). Linear and binary logistic models were used to estimate the independent contribution of sNfL for changes in MRI and Expanded Disability Status Scale (EDSS). Age‐corrected sNfL z‐scores from a normative database of healthy controls were used for sensitivity analyses.Results: High sNfL levels at baseline were associated with atrophy measures of the whole brain (standardized beta coefficient βj = −0.352, p < 0.001), white matter (βj = −0.229, p = 0.007), thalamus (βj = −0.372, p = 0.004), and putamen (βj = −1.687, p = 0.012). pwMS with high levels of sNfL at baseline and follow‐up had a greater risk of EDSS worsening (p = 0.007).Conclusions: Already single time point elevation of sNfL has a distinct effect on brain volume changes over a short‐term period, and repeated high levels of sNfL indicate accumulating physical disability. Serial assessment of sNfL may provide added value in the clinical management of pwMS.

Verified
Journal Article
Open access
PDF file
MSMichael Seiberl
Michael Seiberl
JFJulia Feige
Julia Feige
PHPatrick Hilpold
Patrick Hilpold
Wolfgang HitzlWolfgang Hitzl
Wolfgang Hitzl
LMLukas Machegger
Lukas Machegger
TMTobias Moser
Tobias Moser
Serum neurofilament light chain (sNfL) is an intensely investigated biomarker in multiple sclerosis (MS). The aim of this study was to explore the impact of cladribine (CLAD) on sNfL and the potential of sNfL as a predictor of long-term treatment response. Data were gathered from a prospective, real-world CLAD cohort. We measured sNfL at baseline (BL-sNfL) and 12 months (12Mo-sNfL) after CLAD start by SIMOA. Clinical and radiological assessments determined fulfilment of “no evidence of disease activity” (NEDA-3). We evaluated BL-sNfL, 12M-sNfL and BL/12M sNfL ratio (sNfL-ratio) as predictors for treatment response. We followed 14 patients for a median of 41.5 months (range 24.0–50.0). NEDA-3 was fulfilled by 71%, 57% and 36% for a period of 12, 24 and 36 months, respectively. We observed clinical relapses in four (29%), MRI activity in six (43%) and EDSS progression in five (36%) patients. CLAD significantly reduced sNfL (BL-sNfL: mean 24.7 pg/mL (SD ± 23.8); 12Mo-sNfL: mean 8.8 pg/mL (SD ± 6.2); p = 0.0008). We found no correlation between BL-sNfL, 12Mo-sNfL and ratio-sNfL and the time until loss of NEDA-3, the occurrence of relapses, MRI activity, EDSS progression, treatment switch or sustained NEDA-3. We corroborate that CLAD decreases neuroaxonal damage in MS patients as determined by sNfL. However, sNfL at baseline and at 12 months failed to predict clinical and radiological treatment response in our real-world cohort. Long-term sNfL assessments in larger studies are essential to explore the predictive utility of sNfL in patients treated with immune reconstitution therapies.

16 March 2022 in Medicina
Verified
Journal Article
Open access
PDF file
DKDaniela Kern
Daniela Kern
MKMichael Khalil
Michael Khalil
LPLukas Pirpamer
Lukas Pirpamer
ABArabella Buchmann
Arabella Buchmann
EHEdith Hofer
Edith Hofer
RSReinhold Schmidt
Reinhold Schmidt
Background and Objectives: The neurofilament light chain (NfL) is a biomarker for neuro-axonal injury in various acute and chronic neurological disorders, including Alzheimer’s disease (AD). We here investigated the cross-sectional and longitudinal associations between baseline serum NfL (sNfL) levels and cognitive, behavioural as well as MR volumetric findings in the Prospective Dementia Registry Austria (PRODEM-Austria). Materials and Methods: All participants were clinically diagnosed with AD according to NINCDS-ADRDA criteria and underwent a detailed clinical assessment, cognitive testing (including the Mini Mental State Examination (MMSE) and the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD)), the neuropsychiatric inventory (NPI) and laboratory evaluation. A total of 237 patients were included in the study. Follow-up examinations were done at 6 months, 1 year and 2 years with 93.3% of patients undergoing at least one follow-up. We quantified sNfL by a single molecule array (Simoa). In a subgroup of 125 subjects, brain imaging data (1.5 or 3T MRI, with 1 mm isotropic resolution) were available. Brain volumetry was assessed using the FreeSurfer image analysis suite (v6.0). Results: Higher sNfL concentrations were associated with worse performance in cognitive tests at baseline, including CERAD (B = −10.084, SE = 2.999, p < 0.001) and MMSE (B = −3.014, SE = 1.293, p = 0.021). The sNfL levels also correlated with the presence of neuropsychiatric symptoms (NPI total score: r = 0.138, p = 0.041) and with smaller volumes of the temporal lobe (B = −0.012, SE = 0.003, p = 0.001), the hippocampus (B = −0.001, SE = 0.000201, p = 0.013), the entorhinal (B = −0.000308, SE = 0.000124, p = 0.014), and the parahippocampal cortex (B = −0.000316, SE = 0.000113, p = 0.006). The sNfL values predicted more pronounced cognitive decline over the mean follow-up period of 22 months, but there were no significant associations with respect to change in neuropsychiatric symptoms and brain volumetric measures. Conclusions: the sNfL levels relate to cognitive, behavioural, and imaging hallmarks of AD and predicts short term cognitive decline.

17 November 2023 in European Journal of Neurology
Verified
Journal Article
Open access
SFSebastian Franthal
Sebastian Franthal
MKMichael Khalil
Michael Khalil
DKDaniela Kern
Daniela Kern
LGLukas Gattermeyer
Lukas Gattermeyer
ABArabella Buchmann
Arabella Buchmann
Petra SchwingenschuhPetra Schwingenschuh
Petra Schwingenschuh
Background and purpose: Quantification of neurofilament light chain protein in serum (sNfL) enables the neuro‐axonal damage in peripheral blood to be reliably assessed and monitored. There is a long‐standing debate whether essential tremor represents a ‘benign’ tremor syndrome or whether it is linked to neurodegeneration. This study aims to investigate sNfL concentrations in essential tremor compared to healthy controls (cross‐sectionally and longitudinally) and to assess whether sNfL is associated with motor and nonmotor markers of disease progression.Methods: Data of patients with essential tremor from our prospective registry on movement disorders (PROMOVE) were retrospectively analysed. Age‐, sex‐ and body‐mass‐index‐matched healthy controls were recruited from an ongoing community‐dwelling aging cohort. sNfL was quantified by an ultra‐sensitive single molecule array (Simoa). All participants underwent detailed clinical examination at baseline and after approximately 5 years of follow‐up.Results: Thirty‐seven patients with clinically diagnosed essential tremor were included and 37 controls. The essential tremor group showed significantly higher sNfL levels compared to healthy controls at baseline and follow‐up. sNfL levels increased over time in both groups, and the slope of sNfL increase was similar in the essential tremor and healthy control groups. Comparing patients with a disease duration under 5 years to those with a longer disease duration, the former group had a significantly greater increase of sNfL over time, which strongly correlated to worsening of tremor and cognition.Conclusion: Our findings indicate that neurodegeneration, possibly happening at an early disease stage, might play a role in the pathophysiology of essential tremor.

26 August 2021 in Frontiers in Immunology
Verified
Journal Article
Open access
TMTobias Moser
Tobias Moser
MSMichael Seiberl
Michael Seiberl
JFJulia Feige
Julia Feige
LBLara Bieler
Lara Bieler
RRRichard F. Radlberger
Richard F. Radlberger
PWPeter Wipfler
Peter Wipfler
Background: Efficacy of vaccines and disease activity linked to immunization are major concerns among people with multiple sclerosis (pwMS).Objective: To assess antibody responses to seasonal influenza antigens and vaccine-associated neuroaxonal damage utilizing serum neurofilament light chain (sNfL) in pwMS receiving dimethyl fumarate (DMF).Methods: In this prospective study, the 2020/2021 seasonal tetravalent influenza vaccine was administered to 20 pwMS treated with DMF and 15 healthy controls (HCs). The primary endpoints were responder rate of strain-specific antibody production (seroconversion or significant (4-fold) increase in influenza-antibody titers for ≥2/4 strains) at 30 days post-vaccination and changes in sNfL levels.Results: All patients treated with DMF fulfilled the responder criteria for immunization compared with 53% of the controls. However, higher proportions of HCs already had influenza-antibody titers ≥1:40 at baseline (53% vs. 41%, p = 0.174). sNfL levels were comparable among both groups at baseline and did not increase 34 days after vaccination. In addition, no clinical or radiological disease reactivation was found.Conclusion: DMF-treated patients mount an adequate humoral immune response to influenza vaccines. Within the limits of the small cohort investigated, our data suggest that influenza immunization is not associated with clinical or subclinical disease reactivation.